Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension

European Journal of Pharmacology

Volumn 682, Issue 1-3, 2012, Pages 131-136

  Sakamoto, Aiko ^a   Hongo, Makiko ^a   Saito, Kan ^a   Nagai, Ryozo ^a   Ishizaka, Nobukazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II; Kidney; Lipid accumulation; Peroxisome proliferator activated receptor; Proteinuria

Indexed keywords

ANGIOTENSIN II; CHOLESTEROL; FERRITIN; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IRON; MESSENGER RNA; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FAS GENE; GENE; GENE EXPRESSION; HISTOLOGY; HYPERTENSION; KIDNEY INJURY; KIDNEY MASS; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEINURIA; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SREBP 1C GENE; SYSTOLIC BLOOD PRESSURE; UPREGULATION; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; DISEASE MODELS, ANIMAL; FERRITINS; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; HYPERTENSION; IRON; KIDNEY; LIPID METABOLISM; MALE; PPAR GAMMA; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 84859101058     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.02.027     Document Type: Article

References (45)

1. T. Aizawa, N. Ishizaka, J. Taguchi, R. Nagai, I. Mori, S.S. Tang, J.R. Ingelfinger, and M. Ohno Heme oxygenase-1 is upregulated in the kidney of angiotensin II-induced hypertensive rats: possible role in renoprotection Hypertension 35 2000 800 806
2. A. Benigni, C. Zoja, S. Tomasoni, M. Campana, D. Corna, C. Zanchi, E. Gagliardini, E. Garofano, D. Rottoli, T. Ito, and G. Remuzzi Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone J. Am. Soc. Nephrol. 17 2006 1624 1632
3. I.A. Bobulescu Renal lipid metabolism and lipotoxicity Curr. Opin. Nephrol. Hypertens. 19 2010 393 402
4. I.A. Bobulescu, M. Dubree, J. Zhang, P. McLeroy, and O.W. Moe Reduction of renal triglyceride accumulation: effects on proximal tubule Na+/H + exchange and urinary acidification Am. J. Physiol. Ren. Physiol. 297 2009 F1419 F1426
5. L. Chen, R.A. Boadle, and D.C. Harris Toxicity of holotransferrin but not albumin in proximal tubule cells in primary culture J. Am. Soc. Nephrol. 9 1998 77 84
6. K. Cusi Nonalcoholic fatty liver disease in type 2 diabetes mellitus Curr. Opin. Endocrinol. Diab. Obes. 16 2009 141 149
7. J. Dominguez, P. Wu, C.S. Packer, C. Temm, and K.J. Kelly Lipotoxic and inflammatory phenotypes in rats with uncontrolled metabolic syndrome and nephropathy Am. J. Physiol. Ren. Physiol. 293 2007 F670 F679
8. P.D. Hockings, K.K. Changani, N. Saeed, D.G. Reid, J. Birmingham, P. O'Brien, J. Osborne, C.N. Toseland, and R.E. Buckingham Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats Diab. Obes. Metab. 5 2003 234 243
9. M. Hongo, N. Ishizaka, K. Furuta, N. Yahagi, K. Saito, R. Sakurai, G. Matsuzaki, K. Koike, and R. Nagai Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart Eur. J. Pharmacol. 604 2009 87 92
10. X. Hou, Y.H. Shen, C. Li, F. Wang, C. Zhang, P. Bu, and Y. Zhang PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity Biochem. Biophys. Res. Commun. 394 2010 653 659
11. N. Ishizaka, T. Aizawa, I. Yamazaki, S. Usui, I. Mori, K. Kurokawa, S.S. Tang, J.R. Ingelfinger, M. Ohno, and R. Nagai Abnormal iron deposition in renal cells in the rat with chronic angiotensin II administration Lab. Investig. 82 2002 87 96
12. N. Ishizaka, G. Matsuzaki, K. Saito, E. Noiri, I. Mori, and R. Nagai Expression and localization of PDGF-B, PDGF-D, and PDGF receptor in the kidney of angiotensin II-infused rat Lab. Investig. 86 2006 1285 1292
13. T. Jiang, Z. Wang, G. Proctor, S. Moskowitz, S.E. Liebman, T. Rogers, M.S. Lucia, J. Li, and M. Levi Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway J. Biol. Chem. 280 2005 32317 32325
14. A. Kamijo, K. Kimura, T. Sugaya, M. Yamanouchi, H. Hase, T. Kaneko, Y. Hirata, A. Goto, T. Fujita, and M. Omata Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage Kidney Int. 62 2002 1628 1637
15. Y. Kamijo, K. Hora, K. Kono, K. Takahashi, M. Higuchi, T. Ehara, K. Kiyosawa, H. Shigematsu, F.J. Gonzalez, and T. Aoyama PPARalpha protects proximal tubular cells from acute fatty acid toxicity J. Am. Soc. Nephrol. 18 2007 3089 3100
16. E. Katsoulieris, J.G. Mabley, M. Samai, M.A. Sharpe, I.C. Green, and P.K. Chatterjee Lipotoxicity in renal proximal tubular cells: relationship between endoplasmic reticulum stress and oxidative stress pathways Free Radic. Biol. Med. 48 2010 1654 1662
17. X. Kong, D.Y. Zhang, H.B. Wu, and F.X. Li Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats Biol. Pharm. Bull. 34 2011 693 699
18. G. Kronke, A. Kadl, E. Ikonomu, S. Bluml, A. Furnkranz, I.J. Sarembock, V.N. Bochkov, M. Exner, B.R. Binder, and N. Leitinger Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors Arterioscler. Thromb. Vasc. Biol. 27 2007 1276 1282
19. G. Lemieux, B. Moulin, J. Davignon, and Y.S. Huang The lipid content of the diabetic kidney of the rat Can. J. Physiol. Pharmacol. 62 1984 1274 1278
20. H. Li, X.Z. Ruan, S.H. Powis, R. Fernando, W.Y. Mon, D.C. Wheeler, J.F. Moorhead, and Z. Varghese EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism Kidney Int. 67 2005 867 874
21. R. Marfella, C. Di Filippo, M. Portoghese, M. Barbieri, F. Ferraraccio, M. Siniscalchi, F. Cacciapuoti, F. Rossi, M. D'Amico, and G. Paolisso Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome J. Lipid Res. 50 2009 2314 2323
22. J.F. Moorhead, M.K. Chan, M. El-Nahas, and Z. Varghese Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease Lancet 2 1982 1309 1311
23. T. Namikoshi, N. Tomita, M. Satoh, Y. Haruna, S. Kobayashi, N. Komai, T. Sasaki, and N. Kashihara Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet Hypertens. Res. 31 2008 745 755
24. T. Ogihara, T. Asano, K. Ando, Y. Chiba, H. Sakoda, M. Anai, N. Shojima, H. Ono, Y. Onishi, M. Fujishiro, H. Katagiri, Y. Fukushima, M. Kikuchi, N. Noguchi, H. Aburatani, I. Komuro, and T. Fujita Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling Hypertension 40 2002 872 879
25. S. Ohtomo, Y. Izuhara, S. Takizawa, N. Yamada, T. Kakuta, C. van Ypersele de Strihou, and T. Miyata Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model Kidney Int. 72 2007 1512 1519
26. F. Omasu, T. Oda, M. Yamada, N. Yoshizawa, K. Yamakami, Y. Sakurai, and S. Miura Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats Am. J. Physiol. Ren. Physiol. 293 2007 F1292 F1298
27. A.C. Ong, and J.F. Moorhead Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int. 45 1994 753 762
28. U. Panchapakesan, X.M. Chen, and C.A. Pollock Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection Nat. Clin. Pract. Nephrol. 1 2005 33 43
29. C.W. Park, H.W. Kim, S.H. Ko, H.W. Chung, S.W. Lim, C.W. Yang, Y.S. Chang, A. Sugawara, Y. Guan, and M.D. Breyer Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha Diabetes 55 2006 885 893
30. C.W. Park, Y. Zhang, X. Zhang, J. Wu, L. Chen, D.R. Cha, D. Su, M.T. Hwang, X. Fan, L. Davis, G. Striker, F. Zheng, M. Breyer, and Y. Guan PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney Int. 69 2006 1511 1517
31. C.A. Pollock, and P. Poronnik Albumin transport and processing by the proximal tubule: physiology and pathophysiology Curr. Opin. Nephrol. Hypertens. 16 2007 359 364
32. N. Rasouli, U. Raue, L.M. Miles, T. Lu, G.B. Di Gregorio, S.C. Elbein, and P.A. Kern Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue Am. J. Physiol. Endocrinol. Metab. 288 2005 E930 E934
33. G.V. Richieri, and A.M. Kleinfeld Unbound free fatty acid levels in human serum J. Lipid Res. 36 1995 229 240
34. K. Saito, N. Ishizaka, M. Hara, G. Matsuzaki, M. Sata, I. Mori, M. Ohno, and R. Nagai Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II Hypertension 46 2005 1180 1185
35. Sakamoto, A., Hongo, M., Furuta, K., Saito, K., Nagai, R., Ishizaka, N., in press. Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int. J. Cardiol.
36. S.J. Shin, J.H. Lim, S. Chung, D.Y. Youn, H.W. Chung, H.W. Kim, J.H. Lee, Y.S. Chang, and C.W. Park Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats Hypertens. Res. 32 2009 835 845
37. Y. Sui, H.L. Zhao, R.R. Fan, J. Guan, L. He, H.M. Lee, J.C. Chan, and P.C. Tong Renin-angiotensin system activation in renal adipogenesis Am. J. Physiol. Ren. Physiol. 298 2010 F391 F400
38. L. Sun, N. Halaihel, W. Zhang, T. Rogers, and M. Levi Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus J. Biol. Chem. 277 2002 18919 18927
39. M.E. Thomas, and G.F. Schreiner Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin Am. J. Nephrol. 13 1993 385 398
40. D.H. van Raalte, N.J. van der Zijl, and M. Diamant Pancreatic steatosis in humans: cause or marker of lipotoxicity? Curr. Opin. Clin. Nutr. Metab. Care 13 2010 478 485
41. J.M. Weinberg Lipotoxicity Kidney Int. 70 2006 1560 1566
42. T. Yoshimoto, M. Naruse, M. Nishikawa, K. Naruse, A. Tanabe, T. Seki, T. Imaki, R. Demura, E. Aikawa, and H. Demura Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats Am. J. Physiol. 272 1997 E989 E996
43. T. Yotsumoto, T. Naitoh, T. Kanaki, M. Matsuda, and N. Tsuruzoe A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation Metabolism 52 2003 1633 1637
44. Y.T. Zhou, P. Grayburn, A. Karim, M. Shimabukuro, M. Higa, D. Baetens, L. Orci, and R.H. Unger Lipotoxic heart disease in obese rats: implications for human obesity Proc. Natl. Acad. Sci. U. S. A. 97 2000 1784 1789
45. Y. Zhou, X. Kong, P. Zhao, H. Yang, L. Chen, J. Miao, X. Zhang, J. Yang, J. Ding, and Y. Guan Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury Kidney Int. 79 2011 1302 1311